The article discusses recent regulatory actions and safety concerns regarding Garcinia cambogia, a plant commonly used in dietary supplements, particularly for weight loss.
Key Points:
-
France’s Ban:
- France initially banned Garcinia cambogia in 2012 for medicinal use due to safety concerns. A recent order, effective April 2025, extends this ban to food supplements for two years, citing adverse health reports linked to the ingredient.
-
European Food Safety Authority (EFSA) Actions:
- EFSA issued a draft opinion asserting insufficient data on safe daily intake and long-term effects of hydroxycitric acid (HCA), the active compound in Garcinia. They noted issues like inadequate clinical studies and product characterization.
- The draft has drawn concerns from various European bodies, leading to calls for further data from manufacturers regarding the ingredient’s safety.
-
Global Regulatory Actions:
- Ongoing liver toxicity concerns are prompting regulatory measures worldwide:
- United States: The FDA recalled weight-loss products in 2009 due to liver injury reports and some states are restricting sales to minors.
- China: No outright ban, but stringent pre-market approvals are required.
- Australia: Warning labels regarding liver harm are now mandatory on products.
- South Korea: New regulations include warning labels and limitations on the combination of ingredients.
- Ongoing liver toxicity concerns are prompting regulatory measures worldwide:
-
Future Considerations:
- The EFSA’s final opinion is expected by February 2027, potentially placing HCA under increased scrutiny or prohibition depending on new findings.
- Stakeholders may face implications based on broader legal decisions affecting regulatory compliance in the EU.
Conclusion:
The ongoing scrutiny and regulatory developments regarding Garcinia cambogia reflect growing health concerns and highlight the need for robust safety data in dietary supplements. As agencies continue to evaluate the risks, the future of HCA in the market remains uncertain.
